News

People with hypoparathyroidism experience extensive changes in bone microstructure compared with the general population, a pilot study revealed. Such changes appear to be more prominent in patients whose disease has a cause other than surgery. Factors such as age, menstrual status in women, and treatment duration in men…

ProLynx has been awarded a small business innovation research grant from the National Institutes of Health (NIH) to develop its long-acting parathyroid hormone (PTH) therapy — known as PTH(1-34) — for people with hypoparathyroidism. Hypoparathyroidism is an uncommon condition characterized by low levels of PTH,…

People with hypoparathyroidism whose disease cannot be sustainably controlled with conventional treatment and parathyroid hormone (PTH) infusions may benefit from a continuous PTH infusion using an insulin pump, a case series suggests. The approach was found to be safe and to control the disease for 5.5 years or…

People who undergo surgery to remove the entire thyroid gland have a much higher incidence of chronic hypoparathyrodism than previously reported, with younger patients and those with so-called toxic thyroid disease at particular risk, a study in Denmark found. The study, “High incidence of…

Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism treatment known as AZP-3601 later this year. “Our new name, Amolyt Pharma, is derived from ammolite, a rare gemstone originating from living organisms,” Thierry Abribat, PhD, the company’s founder and…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.